iShares Biotechnology ETF
608 hedge funds and large institutions have $6.14B invested in iShares Biotechnology ETF in 2018 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 171 increasing their positions, 227 reducing their positions, and 58 closing their positions.
8% more capital invested
Capital invested by funds: $5.68B → $6.14B (+$457M)
4.75% more ownership
Funds ownership: 62.98% → 67.73% (+4.8%)
7% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 58
0% more funds holding
Funds holding: 607 → 608 (+1)
8% less funds holding in top 10
Funds holding in top 10: 25 → 23 (-2)
17% less call options, than puts
Call options by funds: $411M | Put options by funds: $495M
25% less repeat investments, than reductions
Existing positions increased: 171 | Existing positions reduced: 227
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$164M |
| 2 |
Goldman Sachs
New York
|
+$163M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$68.3M |
| 4 |
Citigroup
New York
|
+$62.9M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$32.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$49.1M |
| 2 |
JG
Jefferies Group
New York
|
-$38.2M |
| 3 |
NM
NWI Management
New York
|
-$26.7M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$21.9M |
| 5 |
SF
Synovus Financial
Columbus,
Georgia
|
-$20.7M |
IBB Hedge Fund Activity: Q2 2018 in Review
608 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2018, worth a combined $6.14B — up 8% from $5.68B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new IBB positions and 58 closed out — a net gain of 4 holders — while 171 added to existing stakes and 227 trimmed.
The largest buyer was UBS Group, adding an estimated $164M. The largest seller was Deutsche Bank, cutting an estimated $49.1M.
- 608 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2018, up from 607 in Q1 2018.
- Funds reported $6.14B of iShares Biotechnology ETF stock for Q2 2018, up 8% quarter-over-quarter.
- 62 funds opened new iShares Biotechnology ETF positions in Q2 2018 and 58 closed out, a net change of +4 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2018 was UBS Group, an estimated $164M added.
- The largest iShares Biotechnology ETF seller in Q2 2018 was Deutsche Bank, an estimated $49.1M sold.
Based on aggregated 13F filings for Q2 2018.